

Yale Eye Center Grand Rounds

“The Future of Vision Chip Implants and Robotic Surgery”

Friday, October 2, 2020
7:00 am – 8:15 am

Zoom
Meeting ID: 997 1899 0880

Course Director:
Ron A. Adelman, MD, MPH, MBA

There is no corporate support for this activity.

This course will fulfill the licensure requirement set forth by the State of Connecticut.



James T. Handa, MD

Robert Bond Welch, MD Professor
Chief, The Retina Division
Department of Ophthalmology
Wilmer Eye Institute
Johns Hopkins University School of
Medicine

ACCREDITATION

The Yale School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

TARGET AUDIENCE

Eye care professionals.

NEEDS ASSESSMENT

Visual rehabilitation for patients with severe vision loss is a well-established gap in clinical care. Inherited retinal dystrophies are blinding diseases that affect 1 in 3500 people (Verbakel SK et al. Prog Retin Eye Res. 2018 Sep;66:157-186; PMID: 29597005). While gene therapy offers the potential for restoring vision, many gaps remain

before widespread use can be implemented. The ARGUS II implant was approved by the FDA in 2013 for severe vision loss due to inherited retinal dystrophies. Despite 153 publications on the ARGUS II, ophthalmologists are unfamiliar with this technology. Likewise the emergence of robotic surgery has provided new opportunities for advancing ophthalmologic surgery (Channa R, Iordachita I, Handa JT. Retina. 2017 Jul;37(7):1220-1228. PMID: 27893625).

LEARNING OBJECTIVES

At the conclusion of the conference, meeting participants will be able to:

- Understand the pros and cons of the

Argus II implant.

- Provide insight into alternative vision chip implants
- To provide background robotic surgery for ophthalmology and its potential to improve surgery

DESIGNATION STATEMENT

The Yale School of Medicine designates this live activity for 1.5 AMA PRA Category 1 Credit(s)™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

FACULTY DISCLOSURES

Speaker: James Handa, MD – Bayer Pharmaceuticals, PI
Course Director: Ron A. Adelman, MD, MPH, MBA - NONE

It is the policy of Yale School of Medicine, Continuing Medical Education, to ensure balance, independence, objectivity and scientific rigor in all its educational programs. All faculty participating as speakers in these programs are required to disclose any relevant financial relationship(s) they (or spouse or partner) have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 12 months; and the opportunity to affect the content of CME about the products or services of the commercial interests. The Center for Continuing Medical Education will ensure that any conflicts of interest are resolved before the educational activity occurs.

